

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
28 July 2005 (28.07.2005)

PCT

(10) International Publication Number
WO 2005/067922 A1

(51) International Patent Classification⁷: **A61K 31/4035**,
C07D 209/48, 403/06, 209/34, A61K 31/4045, A61P
25/16

(21) International Application Number:
PCT/IN2004/000214

(22) International Filing Date: 16 July 2004 (16.07.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/MUM/2004 20 January 2004 (20.01.2004) IN

(71) Applicant (for all designated States except US): **USV
LIMITED** [IN/IN]; B.S.D. Marg, Station Road, Govandi,
Mumbai 400 088, Maharashtra (IN).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **TARUR, Venkata-
subramanian, Radhakrishnan** [IN/IN]; A-301, Vaishali
Towers, B.R. Road, Mulund West, Mumbai 400 080,
Maharashtra (IN). **SATHE, Dhananjay, Govind** [IN/IN];
H-15, Rajdeep CHS, Gokhale Road, Naupada, Thane
400 602, Maharashtra (IN). **MONDKAR, Harish,
Kashinath** [IN/IN]; 5/22, Samant Blocks, Cama Road,
Andheri (West), Mumbai 400 058, Maharashtra (IN).
BHOPALKAR, Rajesh, Ganpat [IN/IN]; 11, 4th Floor,
Jejuri Apartments, Brahmin Society, Naupada 400 602,
Maharashtra (IN). **PATIL, Samadhan, Daulat** [IN/IN];
C-49, Nileshwari Palace, Devi Chowk, Shastri Nagar,
Dombivli (West) 421 202, Maharashtra (IN).

(74) Agent: **NAIR, Gopakumar, G.**; Patents & Trademark
Agent (Regd.), Gopakumar Nair Associates, Nair Baug,
Akurli Road, Kandivli (East), Mumbai 400 101 (IN).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,

GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted
a patent (Rule 4.17(ii)) for the following designations AE,
AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ,
CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE,
EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,
JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,
MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM,
PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ,
TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM,
ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA,
SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE,
BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG)
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii)) for the following desig-
nations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW,
BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ,
EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID,
IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ,
OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM,
ZW, ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, NA,
SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE,
BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI patent
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG)

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: A PROCESS FOR THE PREPARATION OF 4-(2-DIPROPYLAMINOETHYL)-1,3-DIHYDRO-2H-INDOL-2-ONE
HYDROCHLORIDE

(57) Abstract: The present invention discloses a novel process and novel intermediates for the Preparation of 4-[2-(di-n-propyl
amino) ethyl]-1,3-dihydro-2H-indol-2-one, commonly known as Ropinirole (I) and pharmaceutical composition comprising the
same. Further the present invention also discloses a method of treatment for cardiovascular disorders and Parkinson's disease.

WO 2005/067922 A1

A process for the preparation of 4-(2-Dipropylaminoethyl)-1,3-dihydro-2H-indol-2-one hydrochloride

Related Application

This application claims priority from India National patent application serial No. 60/MUM/2003, filed 20 Jan 04.

Technical field of invention

The present invention relates to a novel process and novel intermediates for the preparation of 4-[2-(di-n-propyl amino)ethyl]-1,3-dihydro-2H-indol-2-one, commonly known as Ropinirole.

Background and Prior Art:

Ropinirole is described in US 4,452,808 as being useful in cardiovascular therapy and in US 4,824,860 as an agent useful in treating Parkinson's disease. The processes for the preparation of Ropinirole HCl and its derivatives have previously been described. US 4,452,808 describes the preparation of 4-aminoalkyl-2(3H)-indolones starting from either 4-aminoalkyl-7hydroxy-2(3H)-indolones or 2-methyl-3-nitro-benzene acetic acid by two different processes. Particularly those processes involving reductive cyclization of nitrostyrene intermediates in presence of acetyl chloride and Iron (III) chloride described in EP 0300614 and WO 91/16306 are of particular relevance. Present invention discloses a novel route and novel intermediates for the preparation of Ropinirole. Present invention comprises of 6 steps leading to desired moiety.


US Patents namely US 4452808, US 5336781, US 4997954, US 4314944 deal with the

molecule called Ropinirole. For the present purpose US 4452808 and US 4314944 are more relevant. Few patents deal with Ropinirole mainly from method of treatment point of view and therefore are not directly related to the present invention.

WO 91/16306 and EP 0300614 are relevant from the point of view of reductive cyclization and are dealt at appropriate place hereafter.

The processes for the preparation of Ropinirole HCl and its derivatives have previously been described. US 4,452,808 describes the preparation of 4-aminoalkyl-2(3H)-indolones starting from either 4-aminoalkyl-7-hydroxy-2(3H)-indolones or 2-methyl -3-nitro-benzene acetic acid by two different processes. The 7-hydroxy intermediate (i) is first converted to its tetrazolo derivative (ii) which is then hydrogenated to get Ropinirole as shown in Scheme 1. Preparation of 7-hydroxy intermediate (i) is described in US4314944 by following a series of steps starting from p-methoxy phenethylamine. Second process described in US4452808 allows preparation of Ropinirole by following a series of steps starting from 2-methyl-3-nitro benzeneacetic acid.


Scheme 1




Particularly those processes involving reductive cyclization of nitro styrene intermediates in presence of acetyl chloride and Iron (III) chloride described in EP 0300614 and WO 91/16306, are of relevance, as far as this invention is concerned.

Scheme 2 depicts the route disclosed in EP0300614. EP0300614 describes the preparation of Ropinirole by condensation of 4-[2-(bromoethyl)-1,3-dihydro-2H-indol-2-one (iii) with di-n-propyl amine (iv). The intermediate (iii) is prepared by following a series of steps starting from 2-(2-bromoethyl)benzaldehyde. Major drawback is a possible formation of an elimination product due to loss of HBr as shown in Scheme 2. Such reaction can impact the purity of desired product and can influence the yield aspects.

Scheme 2



The process as described in WO 91/16306 is an improved process for the preparation of Ropinirole comprising of number of steps, total of eight starting from Isochroman, to get the final product Ropinirole. It discloses the route wherein condensation of di-n-propylamine with a novel intermediate of formula (v) is carried out. Intermediate (v) is prepared by series of steps starting from Isochroman. The process involves well over 7 steps and therefore is a longer one.



Summary of the invention


The process comprises condensation reaction of 2-(2'-bromoethyl)benzaldehyde and an alkali metal salt of an imide like Potassium Phthalimide to give a Phthalimido derivative. Use of suitable solvent is made of for smooth reaction. Phthalimido derivative is converted to nitrostyrene derivative by modified Henry reaction. This is made to undergo Royer reaction to give chloro-oxindole derivative. Dechlorination of this chloro-oxindole derivative gives Phthalimido oxindole product. Removal of Phthalimide moiety from oxindole leads to formation of aminoethyloxindole. N-alkylation reaction comprising of reductive alkylation or direct alkylation of aminoethyloxindole gives Ropinirole.

Further a pharmaceutical composition comprising a therapeutically effective amount of 4-[2-(di-n-propyl amino)ethyl]-1,3-dihydro-2H-indol-2-one is also disclosed.

A method of treating Parkinson's disease or cardiovascular disorders, the method comprising administering to a patient an effective amount of a product-by-process composition of matter comprising 4-(2-Dipropylaminoethyl)-1,3-dihydro-2H-indol-2-one or its salt wherein the said 4-(2-Dipropylaminoethyl)-1,3-dihydro-2H-indol-2-one or its salt manufactured by the said process is also envisaged as part of this invention.

Detailed Description of the invention


The Gabriel synthesis is well known in the art and consists of treatment of alkyl halide with Potassium phthalimide to form an intermediate N-alkyl phthalimide followed by deprotection to give primary alkyl amine.



In the present invention the Gabriel synthesis is employed to introduce the amino group at the 2 position of ethyl side chain. The process disclosed in the present invention describes preparation of Ropinirole from commercially available 2-(2'-Bromoethyl) benzaldehyde in six synthetic steps and is economical.

The novel process of the present invention can be depicted as shown in the scheme 3.

Scheme- 3




Step A of scheme 3 is a condensation reaction between 2-(2' -haloethyl) benzaldehyde and an alkalimetal salt of an imide such as potassium phthalimide or potassium maleimide, carried out with solvent, preferably in any of the solvent from the class of dipolar aprotic or a lower aliphatic alcohol or an aromatic hydrocarbon or lower aliphatic ketones at temperatures ranging from 0 to 150°C for 1 to 12 hrs followed by isolation of the product directly as a solid by dilution with water followed by filtration or by evaporation of the solvent. The reaction is preferably carried out between 2-(2' -bromo ethyl) benzaldehyde (II , X=Br) and potassium phthalimide in a dipolar aprotic solvent, more preferably in DMF, at temperature range of 30-60 °C for 5 to 12 hrs followed by isolation of III by quenching the reaction mass in water followed by filtration.

Dipolar aprotic solvents are to be construed to mean those solvents, which are so recognized by those skilled in the art. Nonlimiting examples are DMSO, DMF, Acetone.

A lower aliphatic alcohol is to be construed to mean alcohol having a molecular formula comprising of number of carbon atoms either four or less than four including branched chain alcohols. Nonlimiting examples are methanol, ethanol, propanol, isopropyl alcohol, butyl alcohol, tert-butyl alcohol, iso-butyl alcohol. An aromatic hydrocarbon is to be construed to mean one with unsaturated character and a closed ring structure. Nonlimiting examples are benzene, toluene, xylene. A lower aliphatic ketone is to be construed to mean a ketone where total number of carbons is 3 to 6. Nonlimiting examples are acetone, ethyl methyl ketone.

Compound III prepared by the said process is preferably compound VIII




VIII

Step B is a modified Henry reaction. These modifications are to suit the specific purpose of end product to be achieved at the end of stage. It comprises of charging sequentially molar equivalents of nitromethane, acetic acid, n-butylamine and 1 to 2 mole excess of trimethyl orthoformate to a suspension of III in lower aliphatic alcohols preferably methanol and stirring at a temperature range of 30 to 80°C for 15 to 30 hours until the reaction is complete. Completion of reaction can be judged by conventional

TLC techniques. The product IV is isolated by filtration.


Compound IV prepared by the said process is preferably compound IX



IX

Step C is a reductive cyclization of IV comprising of charging of a lower aliphatic acid chloride such as Valeryl Chloride, acetyl chloride, pivalyl chloride, preferably valeryl chloride to a stirred solution of Nitrostyrene (IV) and 3 to 5 molar equivalent of Ferric Chloride in Dichloromethane at 0 to 5°C and stirring the reaction in the range of -10 to 30°C preferably 0 to 10°C for about 18 to 24 hrs until the reaction is complete, The reaction is quenched by adding the mixture to water and the product V is isolated by filtration.

Compound V prepared by the said process is preferably compound X.




X

Step D, is the dechlorination step, comprising charging sequentially a hydrogenation catalyst such as Raney Nickel supported palladium or platinum preferably supported palladium on carbon, an aqueous solution of 5 to 10 molar excess of hydrogen donors like Sodium hypophosphite, hydrazine hydrate, formates, preferably sodium hypophosphite to a solution of V in ethyl acetate and stirring at reflux for about 2 to 4 hrs till the reaction is complete. The suspension is filtered, the cake is extracted in hot acetic acid, the catalyst is filtered and acetic acid filtrate is quenched in water. The product VI is isolated by filtration.

Step D can also be performed in another way. This alternative route comprises of hydrogenating a solution of V in DMF in presence of a reduction catalyst such as Raney Ni or supported Platinum or palladium or under Hydrogen pressure ranging from atmospheric to 10 Kg preferably 5 Kg at temperatures room temperature to 100°C, preferably 60°C and isolating the product VI by filtration of catalyst and evaporation of DMF.

Compound VI prepared by the said process D is preferably XI.



XI

Step E, is a deprotection step comprising stirring alcoholic solution of VI, preferably methanolic solution with 1 to 4 molar equivalents of hydrazine hydrate at 30 to 60°C till

precipitation is complete. The resulting suspension is treated with 1 to 10 molar excess of acid like hydrochloric acid, aqueous, hydrobromic acid, acetic acid preferably acetic acid and the mass is digested at 30-80 °C for 0.5 to 2 hrs. The reaction mass is filtered and filtrate solvent is evaporated and the residue is slurried in solvents like ethanol, isopropyl alcohol, ethyl acetate. The product VII is isolated by filtration as an acid addition salt.

Step E, a deprotection, can also comprise of refluxing an alcoholic solution, preferably Methanolic solution in presence of 2 to 2.5 molar equivalents of alkali metal hydroxides such as sodium hydroxide, potassium hydroxide, Calcium hydroxide, preferably sodium hydroxide till the reaction is complete. Solvent is evaporated and the product is extracted in a suitable solvent like ethyl acetate, tetrahydrofuran, 1,4-dioxane, dichloromethane preferably ethyl acetate.

Step F, an N-alkylation reaction, comprises reductive alkylation or direct alkylation, preferably reductive alkylation. The reductive alkylation comprises reduction of schiff's base generated by reaction between 4-(2-aminoethyl)-2(3H)-indolone (VII) or its acid addition salt with propionaldehyde in an alcohol or acetic acid or ethyl acetate preferably methanol using either a hydride reducing agent or catalytic reduction, preferably catalytic hydrogenation. The catalytic hydrogenation is carried out using catalysts such as Raney Ni, Noble metal catalysts with or without support preferably Noble metal catalysts with support, most preferably Palladium supported on " Activated charcoal", under Hydrogen pressure ranging from atmosphere to 100 psi, at temperature ranging from room temperature to 100 °C, for 5 to 10 hrs till the reaction is complete. The catalyst is then filtered, solvent is evaporated and residue triturated with lower aliphatic alcohol preferably Isopropyl alcohol to get (I).

Direct alkylation comprises charging sequentially alkyl halide (in this case propyl halide) or alkyl sulfonate ester preferably propyl bromide, a base such as alkali metal

hydroxide or carbonate or bicarbonate or trialkyl amine or pyridine preferably alkali metal carbonate most preferably sodium carbonate to a solution of VII or its acid addition salt in a suitable solvent such as water, dipolar aprotic solvent, lower aliphatic alcohol, ketones, aromatic hydrocarbons, esters or ethers preferably dipolar aprotic solvent, most preferably DMF and stirring at a temperature in range of 0 to 100°C for about 2 to 24 hrs till the reaction is complete. The reaction is quenched by adding the mixture to water, extraction with an organic solvent such as ethyl acetate and optionally converting it to its acid addition salt by treating the extract with inorganic acid or an organic acid preferably hydrochloric acid.

Examples

Example 1:

Preparation of 2-(2'-phthalimidoethyl) benzaldehyde (VIII)

To a stirred suspension of potassium phthalimide (1.3 Kg, 7 mol) in DMSO (2.5 L), at 110°C, was added 2-(2'-bromoethyl) benzaldehyde (1 Kg, 4.69 mol) added through a dropping funnel over the period of 0.5 hr. The reaction mixture was then stirred at 110°C for 2.5 hr and cooled to room temperature before being added over the period of 0.5 hr in water (7.5 L). The cream colored solid was filtered at suction, washed with water till neutral and dried overnight at 70°C. This gave the title compound, 1.07 Kg (81.6%) in the form of off white solid.

MS-m/z M+H = 280

NMR (200 MHz) DMSO δ 3.43 (t, 2H, CH₂-Ar); δ 4.0 (t, 2H, CH₂N); δ 7.25-7.89 (m, 8H, Ar-H); δ 10.27 (s, 1H, -CHO).

Example 2:

Preparation of 2-(2'-phthalimido ethyl) β - nitrostyrene (IX)

To a stirred suspension of 2-(2'-phthalimidoethyl) benzaldehyde (900 gm, 3.22 mol), in

methanol (9.0 Lt) were added nitromethane (521ml, 9.65 mol), acetic acid (349ml, 6.1 mol), n-butyl amine (486 ml, 4.72 mol) and trimethyl orthoformate (499 ml, 3 mol) at room temperature. The reaction mixture was then stirred at 30-40°C for 30 hrs. The greenish coloured solid was filtered at suction, washed with chilled methanol (700 ml) and dried at 50°C for 8 hrs. This gave the title compound, 649 gm, (62.5%) in the form of cream coloured solid.

MS-m/z M+H = 323.

NMR (200 MHz) DMSO; δ 3.17 (t, 2H, CH₂-Ar); δ 3.91 (t, 2H, CH₂N); δ 7.26-7.64 (m, 8H Ar-H); δ 8.39 (d, 2H, CH=CH).

Example -3:

Preparation of 4-(2' - phthalimidoethyl)-3-chloro-1,3-dihydro-2H-indol-2one (X)

To a stirred solution of 2-(2' -phthalimido ethyl)- β - nitrostyrene (25 gm 0.0776 mol) in dichloromethane (500.0ml) was added Ferric chloride (62.5 gm, 0.385 mol) at room temperature. The reaction mass was cooled to 3°C and to it was charged valeryl chloride (25 ml, 0.206 mol). The reaction mixture was then stirred at 2-5°C for 24 hrs before being added to ice cold water (750 ml). The quenched reaction mixture was stirred at 5°C for 1 hr before being filtered. The yellow solid was isolated at suction, washed with chilled water (2 Lt) and dried at 50 DC for 14 hrs. This gave the title compound, 14 gm, (53 %) in the form of cream coloured solid.

MS-m/z M+H = 341

NMR (200 MHz) DMSO; δ 3.07 (t, 2H, CH₂-Ar); δ 3.99 (t, 2H, CH₂-N); δ 5.7 (s, 1H COCH)

δ 6.83 (d, 1H, Ar-H); δ 6.95 (d, 1H, Ar-H); δ 7.29 (t, 1H, Ar-H); δ 7.9 (s, 4H, ArH); δ 10.85 (s, 1H, NH).

Example -4

Preparation of 4-(2'-phthalimido ethyl)-1,3-dihydro-2H-indol-2-one (XI)

4-(2'- phthalimidoethyl)-3-chloro-1,3-dihydro-2H-indol-2-one (47 gm, 0.138 mol) and 10 % Pd/C (containing 50% w/w water, 8 gm) were stirred in ethyl acetate (940 ml) and heated to reflux. To this mixture was added aqueous solution of sodium hypophosphite (47 gm, 0.443 mol) in water (168 ml) over the period of 20 minutes. The reaction mixture was heated for further 90 minutes before being cooled to room temperature. The reaction mixture was filtered through Whatmann filter paper and the cake was added to acetic acid (425 ml). The acetic acid suspension was heated for 1 hr at 110° C before being filtered hot through celite bed. Charcoal bed was washed with hot acetic acid (100 ml). The filtrate was cooled to room temperature before being added to ice cold water (5 Lt). The quenched mass was stirred at 10°C for 15 minutes. The yellow solid, which was formed, was collected at suction, washed with water till neutral and dried at 70°C for 14 hrs. This gave the title compound, 36 gm, (85%) as a yellow solid.

MS-m/z M+H = 307

NMR (200 MHz) DMSO; δ 2.8 (t, 2H, CH₂-Ar); δ 3.46 (s, 2H, CH₂-CO); δ 3.79 (t, 2H CH₂N)

δ 6.6-7.02 (m, 3H, Ar-H); δ 7.8 (s, 4H, Ar-H); δ 10.3 (s, 1H, CONH).

Example -5:

Preparation of 4-(2'-phthalimido ethyl) -1,3-dihydro-2H-indol-2-one (XI)

A 10 L pressure reactor was charged with dry Pd/C (30 gm), 4-(2'phthalimidoethyl)-3 -chloro-1,3-dihydro-2H-indol-2-one (300 gm, 0.882 mol), triethylamine (133 gm, 0.952 mol) and dimethylformamide (6 L). The reaction mixture was hydrogenated at 30-50° C and 70-75 psi for 2 hours. The catalyst was filtered at 50°C and filtrate was concentrated in vacuum. Water (1.5 L) was added to residue and slurry was stirred for

30 minutes at 30°C. The solids were filtered at suction and washed with water, and dried in oven at 60-70°C to give title compound as yellow solid (225 gm, 83.3%)

Example -6:

Preparation of 4-(2'-aminoethyl)-1,3-dihydro-2H-indol-2-one hydrochloride (VII)

To a stirred suspension of 4-(2'-phthalimidoethyl)-1,3-dihydro-2H-indol-2-one (35gm, 0.114 mol) in methanol (800 ml) was added a solution of hydrazine hydrate (18ml, 0.369 mol) in methanol (75 ml). The reaction mixture was warmed to 40°C and maintained at 40-42°C for 17 hrs. Acetic acid (87 ml) was then charged before being heated to 60°C. The reaction mixture was stirred at 60°C for further 30 minutes before being cooled to 0° C. The precipitate was filtered and the cake was washed with methanol (100 ml). The filtrate was concentrated to dryness and to the residue was added Isopropyl alcohol (250ml) and ethyl acetate (150ml). The solid suspension was stirred further for 2 hrs at 0-5° C. The brownish solid was filtered at suction, washed with ethyl acetate (100 ml) and dried at 60°C for 5 hr. This gave the material 18 gm, (70%) of product as a brown solid. The solid was stirred with ethanolic HCl(100 ml) at 5-10° C for 2 hrs and filtered at suction, solids washed with chilled (5°C) ethanol. Faint brownish yellow solid mass isolated, which then dried in oven at 60° C for 5 hrs. This gave title compound (12 gm) (75%).

MS-m/z M+H = 177

NMR (200 MHz) DMSO; δ 2.87-2.99 (m, 4H, N-CH₂ & Ar-CH₂); δ 3.51 (s, 2H, CH₂-CO);

δ 6.76 (d, 1H Ar-H); δ 6.86 (d, 1H, Ar-H); δ 7.15 (t, 1H, Ar-H); δ 8.27 (s, 2H, NH₂);

δ 10.49 (s, 1H, CONH).

Example - 7:

Preparation of 4 [2-(di-n-propylamino)ethyl]-1,3-dihydro-2-indol-2-one hydrochloride I

A mixture of 4(2'-aminoethyl)-1,3-dihydro-2H-indol-2-one hydrochloride (5 gm, 0.0235 mol), propionaldehyde (5ml, 0.0687 mol) and 1 gm of 10 % Pd/C (50% wet with water) in methanol (200 ml) was hydrogenated at 5 Kg/cm² hydrogen pressure at room temperature for 24 hrs . The mixture was filtered through celite bed and the bed was washed with methanol (20 ml). The filtrate was concentrated to dryness, slurried in ethanol (40ml) at 5-10°C. The cream coloured solid was collected at suction, washed with ethanol (20 ml) and dried, Yield: 2.86 gm (41 %) as an off white solid. Purity 90%

Example – 8:

To a stirred clear solution of 4-[2-(di-n-propyl amino)ethyl]-1,3-dihydro-2-indol-2-one hydrochloride-I (2.86 gm, 0.084mol), in water (25ml) was added Sodium hydroxide solution (2.5 gm in 2.5ml water) at 0 to 5°C over a period of 30 min., raised the temperature to 25°C to 35°C extracted (2x25ml) with MDC. To this MDC extract, Acetic anhydride (0.625ml, 0.006 mol) was added dropwise at temperature 25°C to 35°C and maintain for 3hrs at same temperature. The MDC layer was washed with 2 x 12.5 ml sodium bicarbonate solution followed by 12.5ml water. MDC layer was evaporated on rotary evaporator under vacuum at 45°C to 50°C till complete removal of solvent. To the obtained residue, 12.5 ml of isopropyl alcohol was added and stirred for 10-15 min at 25°C to 35°C to a clear solution. The reaction mixture was further cooled to 5°C-10°C and to this chilled solution 9 ml of ethanolic hydrochloride was added dropwise to get precipitate of hydrochloride salt of the title compound and further dried. Yield: 2.12 gm (85%) as a bluish-off-white solid , Purity 95%MS-m/z = 261

NMR (200 MHz) DMSO; δ 0.92 (t, 6H, CH₃); δ 1.69 (m, 4H, -CH₂); δ 3.01- 3.15 (m, 8HN (CH₂)₃, Ar-CH₂); δ 3.55 (s, 2H, COCH₂); δ 6.7 (d, 1H, Ar-H); δ 6.8 (s, 1H, Ar-H); δ 7.14 (t, 1H, Ar-H); δ 10.78 (s, 1H, NH).


A pharmaceutical composition comprising a therapeutically effective amount of 4-[2-(di-n-propyl amino)ethyl]-1,3-dihydro-2H-indol-2-one or its salt is prepared by conventional methods are also envisaged as a scope of this invention.

A method of treating Parkinson's disease or cardiovascular disorders, the method comprising administering to a patient an effective amount of a product-by-process composition of matter comprising 4-(2-Dipropylaminoethyl)-1,3-dihydro-2H-indol-2-one or its salt wherein the said 4-(2-Dipropylaminoethyl)-1,3-dihydro-2H-indol-2-one or its salt manufactured by the said process are also envisaged as a scope of this invention.

Note that in the specification including claims, the phrase "a pharmaceutical composition" means at least one pharmaceutical composition (or may include more than one), suitable for treating Parkinson's disease or cardiovascular disorders respectively.


We claim,

1. A process for preparation of compound of structural formula (I)




I

and its acid addition salts, particularly hydrochloride salt, which comprises the steps of: A) Condensing a compound of formula II wherein X is a leaving group,




II

with any alkali metal salt of an imide in a solvent to form compound of formula III




III

B) Treating III with nitromethane in presence of RCOOH , R^1NH_2 and $\text{HC}(\text{OR}^2)_3$ in a polar solvent to form a compound of formula IV, and wherein R is C_{1-4} alkyl preferably methyl, R^1 is C_{1-4} alkyl preferably butyl, R^2 is C_{1-4} alkyl preferably methyl,




IV

C) Treating IV with FeCl₃ and R³COCl, in Dichloromethane, to form compound of formula V, wherein R³ is C₁₋₄ alkyl preferably butyl,




V

D) Treating compound V with a hydrogen donor in presence of reduction catalyst in ethyl acetate, to form a Compound of formula VI,




VI

E) Treating compound VI with hydrazine hydrate or alkali metal hydroxide followed by aqueous halo acid such as hydrochloric acid to form a compound of formula VII,



F) Treating compound VII with propionaldehyde under reducing conditions in presence of a reduction catalyst in solvent such as lower aliphatic alcohol to form a compound of formula (I),




G) Conversion of I to its hydrochloride salt,

H) Purification of hydrochloride salt of I.

2. The process as per claim 1A where X is halo most preferred being bromo.
3. The process as claimed in Claim 1A wherein the solvent used is dipolar aprotic or a lower aliphatic alcohol or an aromatic hydrocarbon or aliphatic ketone or a mixture thereof.
4. The process as claimed in Claim 1A wherein solvent used is dimethyl sulphoxide.
5. The process as claimed in Claim 1A wherein solvent used is dimethyl formamide.
6. The process as claimed in Claim 1A wherein solvent used is acetone.
7. The process as claimed in Claim 1A wherein solvent is mixture of dimethyl sulphoxide, dimethyl formamide and acetone.
8. The process as claimed in 1A wherein solvent is methanol, ethanol, propanol, isopropanol, n-butanol, iso-butanol, t-butanol.
9. The process as claimed in 1A wherein solvent optionally used is toluene or benzene.
10. The process as claimed in 1A wherein solvent optionally used is acetone or ethylmethyl ketone.
11. The process as claimed in Claim 1B wherein the solvent is selected from lower aliphatic alcohols.


12. The process as claimed in Claim 1B and 11 wherein the solvent is selected methanol or ethanol or mixture thereof.
13. The process as claimed in claim 1C, wherein the selected solvent is Chloroform or Carbon tetrachloride or Dichloroethane or a mixture thereof.
14. The process as claimed in 1D wherein hydrogen donor is either hydrogen or sodium hypophosphite or formates like Ammonium formate, Sodium formate, or Formic acid or Hydrazine hydrate.
15. The process as claimed in claim 1D wherein catalyst is 5% to 20% palladium on charcoal.
16. The process as claimed in claim 1D and 15 wherein more preferred percentage for palladium on charcoal is 10%.
17. The process as claimed in Claim 1D wherein reduction catalyst is dimethylformamide.
18. The process as claimed in claim 1D where in catalyst is 5% to 20% palladium on charcoal.
19. The process as claimed in claim 1D and 18 wherein more preferred percentage for palladium on charcoal is 10%.
20. The process as claimed in claim 1F wherein the solvent used is methanol.
21. The process as claimed in claim 1F wherein the solvent used is ethanol.

22. The process as per claim 1F wherein the catalyst is 5% to 20% palladium on charcoal.
23. The process as claimed in claim 1F and 22 wherein more preferred percentage for palladium on charcoal is 10%.
24. The process as claimed in Claim 1F wherein the reducing conditions comprise of hydrogen under pressure in the range of 0 to 10kg/cm².
25. The process as claimed in claim 1F wherein more preferred hydrogen pressure conditions is between 4 to 6 kg/ cm².
26. The process as claimed in claim 1A wherein in the alkali metal salt of an imide used is potassium phthalimide.
27. The process as claimed in claims 1 to 26 for preparation of compound VIII and compound VIII




VIII

28. The process as claimed in claims 1 to 26 for preparation of compound IX and compound IX




IX

29. The process as claimed in claims 1 to 26 for preparation of compound X and compound X




X

30. The process as claimed in claims 1 to 26 for preparation of compound XI and compound XI



XI

31. A process for preparation of compound of structural formula (I) and its acid addition salts,



I

particularly hydrochloride salt are substantially described herein with reference to the foregoing examples 1-8.

32. A pharmaceutical composition comprising therapeutically effective amount of 4-(2-Dipropylaminoethyl)-1,3-dihydro-2H-indol-2-one or its salt prepared by the process as claimed in any of the claims 1 to 31.

33. A method of treating Parkinson's disease or cardiovascular disorders, the method comprising administering to a patient an effective amount of a product-by-process composition of matter comprising 4-(2-Dipropylaminoethyl)-1,3-dihydro-2H-indol-2-one or its salt wherein the said 4-(2-Dipropylaminoethyl)-

1,3-dihydro-2H-indol-2-one or its salt manufactured by the process as claimed in any of the claims 1 to 31.

34. A method of treating Parkinson's disease or cardiovascular disorders, using the said pharmaceutical composition as claimed in claim 32.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/IN2004/000214

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K31/4035 C07D209/48 C07D403/06 C07D209/34 A61K31/4045
A61P25/16

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, CHEM ABS Data, BEILSTEIN Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 91/16306 A (SMITH KLINE & FRENCH LABORATORIES LIMITED) 31 October 1991 (1991-10-31) cited in the application the whole document	1-34
Y	EP 0 300 614 A (SMITH KLINE & FRENCH LABORATORIES LIMITED) 25 January 1989 (1989-01-25) cited in the application the whole document	1-34
A	EP 0 299 602 A (SMITH KLINE & FRENCH LABORATORIES LIMITED) 18 January 1989 (1989-01-18)	1-31
X	the whole document	32-34
	----- -/--	



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

° Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *Z* document member of the same patent family

Date of the actual completion of the international search

10 May 2005

Date of mailing of the international search report

24/05/2005

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Gavriiliu, D

INTERNATIONAL SEARCH REPORT

In International Application No
PCT/IN2004/000214

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 4 452 808 A (GALLAGHER, JR. ET AL) 5 June 1984 (1984-06-05) cited in the application	1-31
X	the whole document -----	32-34
Y	US 5 958 965 A (MEWSHAW, RICHARD ERIC ET AL) 28 September 1999 (1999-09-28) the whole document -----	1-34
Y	DATABASE CROSSFIRE BEILSTEIN BEILSTEIN INSTITUT ZUR FOERDERUNG DER CHEMISCHEN WISSENSCHAFTEN, FRANKFURT AM MAIN, DE; 27 June 1988 (1988-06-27), XP002326298 Database accession no. REACTION ID 5572998 abstract & KING ROBINSON: J. CHEM.SOC, 1932, pages 1433-1436, -----	1-31

INTERNATIONAL SEARCH REPORT

International application No.
PCT/IN2004/000214

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 33, 34 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
- No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/IN2004/000214

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9116306	A	31-10-1991	AP 184 A 30-06-1992
			AT 144251 T 15-11-1996
			AU 646771 B2 03-03-1994
			AU 3566993 A 03-06-1993
			AU 640006 B2 12-08-1993
			AU 7656291 A 11-11-1991
			CA 2080221 A1 18-10-1991
			CN 1056686 A ,C 04-12-1991
			CY 1981 A 05-09-1997
			DE 69122753 D1 21-11-1996
			DE 69122753 T2 07-05-1997
			DK 526529 T3 18-11-1996
			EP 0526529 A1 10-02-1993
			ES 2094812 T3 01-02-1997
			FI 924674 A 15-10-1992
			FI 960929 A 28-02-1996
			WO 9116306 A1 31-10-1991
			GR 3022261 T3 30-04-1997
			HK 3097 A 10-01-1997
			HU 64742 A2 28-02-1994
			HU 218210 B 28-06-2000
			IE 911262 A1 23-10-1991
			IL 97867 A 27-11-1995
			IL 111028 A 27-11-1995
			IL 111029 A 27-11-1995
			IL 111030 A 27-11-1995
			JP 3044013 B2 22-05-2000
			JP 10251205 A 22-09-1998
			JP 2788548 B2 20-08-1998
			JP 5506029 T 02-09-1993
			KR 180215 B1 20-03-1999
			MA 22133 A1 31-12-1991
			NO 924028 A ,B, 16-10-1992
			NZ 237819 A 26-05-1993
			NZ 242374 A 26-05-1993
			PL 166736 B1 30-06-1995
			PT 97375 A ,B 31-01-1992
			US 5336781 A 09-08-1994
			ZA 9102782 A 25-11-1992
			EP 0300614
AU 600582 B2 16-08-1990			
AU 1811988 A 22-12-1988			
CA 1326035 C 11-01-1994			
CA 1332948 C 08-11-1994			
CN 1030076 A ,B 04-01-1989			
CY 1951 A 16-05-1997			
DE 3883456 D1 30-09-1993			
DE 3883456 T2 17-03-1994			
DK 334788 A 20-12-1988			
EG 18412 A 30-12-1992			
EP 0300614 A1 25-01-1989			
ES 2058285 T3 01-11-1994			
FI 882919 A ,B, 20-12-1988			
HK 1003226 A1 16-10-1998			
HU 205339 B 28-04-1992			
HU 48583 A2 28-06-1989			
HU 52043 A2 28-06-1990			

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/IN2004/000214

Patent document cited in search report	Publication date	Patent family member(s)	Publication date	
EP 0300614	A	HU 55360 A2	28-05-1991	
		HU 207042 B	01-03-1993	
		IE 62830 B1	08-03-1995	
		IL 86736 A	29-03-1992	
		JP 1019065 A	23-01-1989	
		JP 1974938 C	27-09-1995	
		JP 7000596 B	11-01-1995	
		KR 143088 B1	15-07-1998	
		NO 882588 A ,B,	20-12-1988	
		NZ 225072 A	28-05-1990	
		PH 24608 A	17-08-1990	
		PT 87770 A ,B	31-05-1989	
		US 4997954 A	05-03-1991	
		ZA 8804334 A	25-04-1990	
		EP 0299602	A	18-01-1989
AU 599792 B2	26-07-1990			
AU 1644588 A	24-11-1988			
CA 1305421 C	21-07-1992			
DE 3876877 D1	04-02-1993			
DE 3876877 T2	29-04-1993			
DK 169609 B1	27-12-1994			
EP 0299602 A2	18-01-1989			
ES 2052717 T3	16-07-1994			
GR 3007251 T3	30-07-1993			
HK 1000913 A1	08-05-1998			
HU 47217 A2	28-02-1989			
IE 63511 B1	03-05-1995			
JP 1879525 C	21-10-1994			
JP 6002672 B	12-01-1994			
JP 63303966 A	12-12-1988			
LU 90098 A9	25-09-1997			
MX 9203543 A1	01-07-1992			
NL 970006 I1	01-04-1997			
NZ 224709 A	24-02-1997			
PH 23867 A	23-11-1989			
PT 87542 A ,B	31-05-1989			
US 4824860 A	25-04-1989			
US 4912126 A	27-03-1990			
ZA 8803602 A	26-04-1989			
US 4452808	A	05-06-1984	AT 23038 T	15-11-1986
			AU 560170 B2	02-04-1987
			AU 2158583 A	14-06-1984
			BR 1100036 A3	11-01-2000
			CA 1208650 A1	29-07-1986
			CZ 9103981 A3	17-02-1993
			CY 1497 A	16-02-1990
			DE 3367090 D1	27-11-1986
			DK 562183 A ,B,	08-06-1984
			EG 16556 A	30-01-1989
			EP 0113964 A1	25-07-1984
			ES 8600239 A1	01-01-1986
			ES 8604143 A1	01-06-1986
			FI 834421 A ,B,	08-06-1984
			GR 79121 A1	02-10-1984
			HK 82089 A	20-10-1989
			IE 56347 B1	03-07-1991

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/IN2004/000214

Patent document cited in search report	Publication date	Patent family member(s)	Publication date				
US 4452808	A	IL 70311 A	30-11-1986				
		JP 1050703 B	31-10-1989				
		JP 1565725 C	25-06-1990				
		JP 59112964 A	29-06-1984				
		KR 9101042 B1	21-02-1991				
		LU 90097 A9	16-07-1997				
		MX 9203742 A1	01-07-1992				
		NL 970005 I1	01-04-1997				
		NO 834485 A ,B,	08-06-1984				
		NZ 206344 A	31-03-1987				
		PH 22067 A	20-05-1988				
		PT 77739 A ,B	01-12-1983				
		US 4588740 A	13-05-1986				
		ZA 8309094 A	27-02-1985				
ZW 25883 A1	18-04-1984						
<table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%;">US 5958965</td> <td style="width: 10%;">A</td> <td style="width: 40%;">28-09-1999</td> <td style="width: 20%;">NONE</td> </tr> </table>				US 5958965	A	28-09-1999	NONE
US 5958965	A	28-09-1999	NONE				